MAPT and tauopathy: To determine the effects of expressing the different anti-tau intrabodies prior to overt tauopathy, we unilaterally injected AAVs encoding either the chimeric anti-tau intrabodies fused to ubiquitin (intrabody-K48R, intrabody-K63), conventional intrabody, or AAV-control into the 6 month old P301S-tg mice (n = 4–7 per condition).